About Evommune Inc
- Industry: Biotechnology
- Exchange: NEW YORK STOCK EXCHANGE, INC.
- Country: US
- Website: https://www.evommune.com/
Frequently Asked Questions
What is the 52-week range for EVMN?
The 52-week high is $33.2 and the 52-week low is $6.99.
What is the P/E ratio for EVMN?
The P/E ratio data is currently unavailable.
What is the dividend yield for EVMN?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -46.76%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -606.20%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.63.
Analyst Recommendation Trends
Wall Street analyst consensus for EVMN over the last few months:
Latest EVMN News
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
PALO ALTO, Calif. & NEW YORK, October 01, 2026--Evommune, Inc. (NYSE: EVMN) (the "Company" or "Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today shared additional data from its Phase 2a proof-of-concept trial of EVO301 in adults with moderate-to-severe atopic dermatitis (AD) during a late-breaking oral presentation at the European Academy of Dermatology and Venereology (EADV) 2026 Congress in Vienna,
Evommune Presents Additional Data From Phase 2a Proof-Of-Concept Trial Of EVO301 In Adults With Atopic Dermatitis At EADV 2026 Congress; Plan To Initiate Subcutaneous Phase 2b Dose-Ranging Trial In Mid-2027
Presentation highlights EVO301’s clear therapeutic signal, favorable safety and tolerability profile, and reinforces IL-18 inhibition as a novel, clinically relevant approach to treating atopic dermatitis Biomarker
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
PALO ALTO, Calif. & NEW YORK, September 23, 2026--Evommune, Inc. (NYSE: EVMN) ("Evommune" or the "Company"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that data from the Phase 2a trial of EVO301 in moderate-to-severe atopic dermatitis (AD) will be presented in a late-breaking oral session at the upcoming European Academy of Dermatology & Venereology (EADV) Congress, taking place in Vienna, Aust
Evommune To Present Results From Phase 2a Study Of EVO301 In Moderate-To-Severe Atopic Dermatitis At European Academy Of Dermatology & Venereology Congress
Evommune, Inc. (NYSE:EVMN) ("Evommune" or the "Company"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced
Evommune: Pipeline Reset After EVO756 Failure, All Eyes On EVO301
Evommune is now a clinical 'prove-it' story after the EVO756 Phase 2b failure in atopic dermatitis. Click here to read an analysis of EVMN stock now.
Evommune (EVMN) Drops EVO756 for Eczema. Can EVO301 Carry the Pipeline?
Evommune, Inc. (NYSE:EVMN) announced on September 8 that EVO756 missed its primary endpoint in a randomized, double-blind, placebo-controlled Phase 2b trial involving 121 adults with moderate-to-severe atopic dermatitis. The primary measure was the percentage change from baseline in Eczema Area and Severity Index, or EASI, at week 12. No tested dose met the primary or […]
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
Karyopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gene therapy startup banked $275 million.
Sector Update: Healthcare Stocks Decline in Afternoon Trading
Healthcare stocks were lower Wednesday afternoon, with the NYSE Healthcare Index down 0.3% and the S
This Biotech Has Lost 50%-Plus On Just One Drug; Why It's Still Trucking On
Evommune stock dropped Wednesday after its experimental eczema treatment flopped in midstage testing. The bearish news followed another miss for the drug in treating hives.
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regular session. The company's market cap stands at $361.0 million. bioAffinity Technologies (NASDAQ:BIAF) stock
Leerink Partners Maintains Outperform on Evommune, Lowers Price Target to $22
Leerink Partners analyst Thomas Smith maintains Evommune (NYSE:EVMN) with a Outperform and lowers the price target from $28 to $22.
Evommune Halts Atopic Dermatitis Program Following Trial Failure
On Tuesday, clinical-stage biotechnology company Evommune Inc. (NYSE:EVMN) announced topline results from its dose-ranging Phase 2b trial assessing oral EVO756 for moderate-to-severe atopic dermatitis. Phase 2b Clinical Trial Findings The study evaluated the efficacy and safety profile of oral EVO756, a Mas-related G-protein coupled receptor X2 antagonist. The trial enrolled 121 adult patients with moderate-to-severe atopic dermatitis over an active 12-week treatment period, with researchers mon
RBC Capital Maintains Outperform on Evommune, Lowers Price Target to $21
RBC Capital analyst Brian Abrahams maintains Evommune (NYSE:EVMN) with a Outperform and lowers the price target from $29 to $21.
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Modular Medical (NASDAQ:MODD) shares increased by 11.3% to $3.14 during Wednesday's pre-market session. The market value of their outstanding shares is at $22.9 million. InnovAge Holding (NASDAQ:INNV)
HC Wainwright & Co. Reiterates Neutral on Evommuneto Neutral
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Evommune (NYSE:EVMN) from Neutral to Neutral.
Why Mission Produce Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket
Mission Produce rose 5.5% after beating Q3 earnings and sales estimates; several stocks rallied, while ServiceTitan and Evommune fell premarket.
Why Is EVMN Stock Down 13% After-Hours?
Evommune said on Tuesday that its mid-stage trial involving its experimental eczema pill EVO756 failed a mid-stage study.
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis
PALO ALTO, Calif. & NEW YORK, September 08, 2026--Evommune, Inc. (NYSE: EVMN) (the "Company" or "Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced top-line results from its randomized, double-blind, placebo controlled dose-ranging Phase 2b trial evaluating the efficacy and safety of oral Mas-related G-protein coupled receptor X2 (MRGPRX2) antagonist, EVO756, in adults with moderate-to-sever
Evommune Reveals Top-Line Results From EVO756 Phase 2b Trial In Moderate-To-Severe Atopic Dermatitis; Says Trial Did Not Meet The Primary Endpoint Of Percent Change In Eczema Area And Severity Index Score From Baseline At Week 12; EVO756 Was Generally Well Tolerated; To Continue Phase 2b Development Of EVO756 In Migraine Prophylaxis; Will Not Advance EVO756 In Atopic Dermatitis
Trial did not meet the primary endpoint of percent change in Eczema Area and Severity Index (EASI) score from baseline at Week 12; EVO756 was generally well tolerated- EVO301, the Company’s IL-18BP fusion protein,
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-07-08 | Carver Kyle | +1,000 | $13.26 | $13,260 |
| 2026-07-07 | KIRSCH ARTHUR S | +10,000 | $13.3 | $133,000 |
| 2026-06-22 | Patel Jeegar Pravinkumar | -1,488 | - | - |
| 2026-06-22 | Patel Jeegar Pravinkumar | -1,488 | $22.5 | $33,480 |
| 2026-06-22 | Patel Jeegar Pravinkumar | +1,488 | $3.84 | $5,714 |
| 2026-06-22 | Drew Janice Suzann | -16,161 | - | - |
| 2026-06-22 | Drew Janice Suzann | -3,839 | - | - |
| 2026-06-22 | Drew Janice Suzann | -20,000 | $22.63 | $452,600 |
| 2026-06-22 | Drew Janice Suzann | +16,161 | $2.99 | $48,321 |
| 2026-06-22 | Drew Janice Suzann | +3,839 | $3.84 | $14,742 |
| 2026-06-22 | Pena Luis C. | -7,438 | $22.71 | $168,917 |
| 2026-06-02 | Cohen David E | +15,673 | - | - |
| 2026-06-02 | Cohen David E | -600 | $21.38 | $12,828 |
| 2026-06-02 | Cohen David E | -5,456 | $20.21 | $110,266 |
| 2026-06-02 | KIRSCH ARTHUR S | +15,673 | - | - |
| 2026-06-02 | MCGRAW BENJAMIN F III | +15,673 | - | - |
| 2026-06-01 | Patel Jeegar Pravinkumar | -13,512 | - | - |
| 2026-06-01 | Patel Jeegar Pravinkumar | -16,687 | $22.74 | $379,462 |
| 2026-06-01 | Patel Jeegar Pravinkumar | +13,512 | $3.84 | $51,886 |
| 2026-06-01 | Pena Luis C. | -16,787 | $22.74 | $381,736 |
| 2026-05-28 | Carver Kyle | -15,000 | - | - |
| 2026-05-28 | Carver Kyle | -18,175 | $22.84 | $415,117 |
| 2026-05-28 | Carver Kyle | +15,000 | $2.99 | $44,850 |
| 2026-05-28 | Moss Gregory S. | -14,223 | - | - |
| 2026-05-28 | Moss Gregory S. | -14,223 | $22.83 | $324,711 |
| 2026-05-28 | Moss Gregory S. | +14,223 | $1.71 | $24,321 |
| 2026-04-16 | Patel Jeegar Pravinkumar | +69,315 | - | - |
| 2026-04-16 | Drew Janice Suzann | +73,892 | - | - |
| 2026-04-16 | Carver Kyle | +98,946 | - | - |
| 2026-04-16 | Moss Gregory S. | +115,279 | - | - |
| 2026-04-16 | Bauer Eugene | +51,117 | - | - |
| 2026-04-16 | Pena Luis C. | +291,420 | - | - |
| 2026-02-17 | RA Capital Healthcare Fund LP | +35,868 | $27.88 | $1,000,000 |
| 2026-02-17 | LSP 7 Cooperative UA | +358,680 | $27.88 | $9,999,998 |
| 2026-02-17 | Verduyn-van Weegen Felice Isabel | +358,680 | $27.88 | $9,999,998 |
| 2025-12-19 | Hopfner Robert Lorne | +1,000 | $17.35 | $17,350 |
| 2025-12-09 | Patel Jeegar Pravinkumar | -7,513 | $17.84 | $134,032 |
| 2025-12-09 | Drew Janice Suzann | -5,074 | $17.84 | $90,520 |
| 2025-12-09 | Carver Kyle | -13,290 | $17.84 | $237,094 |
| 2025-12-09 | Moss Gregory S. | -13,624 | $17.84 | $243,052 |
| 2025-12-09 | Bauer Eugene | -1,478 | $17.84 | $26,368 |
| 2025-12-09 | Pena Luis C. | -28,138 | $17.84 | $501,982 |
| 2025-12-08 | Bauer Eugene | +100,000 | - | - |